Matt Hoffman's profile photo

Matt Hoffman

Cranbury

Associate Editorial Director at NeurologyLive

Executive Producer at NeurologyLive Mind Moments

Medical news: @Neurology_Live | @IJMSCtweets | @CGT_Live | @Contagion_Live | @OptometryTimes | @OphthTimes | @ModernRetina | @OTEurope Proud Rowan grad 🦉

Featured in: Favicon neurologylive.com Favicon hcplive.com Favicon newsbreak.com Favicon neurologytimes.com

Articles

  • FDA Approves Vutrisiran for ATTR-CM, Expanding Indication in Amyloidosis

    2 months ago | neurologylive.com | Matt Hoffman

    The FDA has approved vutrisiran (Amvuttra; Alnylam Pharmaceuticals) for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.1This expanded indication makes vutrisiran both the first and the only FDA-approved therapy for both the cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

  • Comorbidity Burden Is Associated With Increased Adverse Events, DMT Discontinuation in MS Clinical Trials

    Mar 5, 2025 | neurologylive.com | Matt Hoffman

    Among a large group of patients with multiple sclerosis (MS), a higher rate of discontinuation of disease-modifying therapies (DMTs) was associated with the presence of 2 or more existing comorbidities, with psychiatric and cardiometabolic disorders showing particularly increased rates of early discontinuation.1 Additionally, data suggest that greater comorbidity burden was associated with higher rates of adverse events of interest (AESIs) such as infection, treatment-emergent autoimmune...

  • FDA Approves Tenecteplase for Acute Ischemic Stroke

    Mar 3, 2025 | neurologylive.com | Matt Hoffman

    The FDA has approved tenecteplase (TNKase; Genentech) for the treatment of acute ischemic stroke (AIS) in adults, according to a Genentech announcement.1 The thrombolytic medicine is an intravenous (IV) tissue plasminogen activator that is clot-dissolving, administered as a single 5-second IV bolus, followed by a 60-minute infusion. The company noted that it will be providing a 25-mg vial configuration in the coming months to support the approval.

  • Tolebrutinib Slows Disability Worsening in GEMINI Trials of Relapsing MS, Despite Failing to Meet Primary End Point

    Sep 19, 2024 | neurologylive.com | Matt Hoffman

    Tolebrutinib, a brain-penetrant and bioactive Bruton’s tyrosine kinase (BTK) inhibitor being investigated by Sanofi as a treatment for relapsing multiple sclerosis (MS) that acts on peripheral B cells, has failed to meet its primary end point of reducing annualized relapse rate (ARR) in comparison with teriflunomide (Aubagio; Sanofi), according to the top line results of the phase 3 GEMINI 1 (NCT04410978) and GEMINI 2 (NCT04410991) clinical trials.1,2 Although, importantly, the trial did show...

  • 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD

    Sep 19, 2024 | neurologylive.com | Peter A Calabresi |Matt Hoffman

    [WATCH TIME: 5 minutes]“The imaging technology has really improved specificity and will help quite a lot.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
1K
Tweets
10K
DMs Open
Yes
No Tweets found.